Abstract
AIM: To gauge patient interest in receiving long-acting injectable nanoformulated antiretroviral therapy.
METHODS: Four hundred adult HIV-infected patients currently prescribed antiretroviral therapy were surveyed. χ(2) tests were used for comparisons of interest across groups.
RESULTS: Respondents were 68% male and 53% African-American, with a mean age of 47 years. Overall, 73% of patients indicated that they would definitely or probably try injectable nanoformulated antiretroviral therapy; 61% with weekly dosing; 72% every 2 weekly; and 84% monthly. In total, 48% indicated that they were very concerned about the possible side effects and 35% were very concerned about needle use.
CONCLUSION: The majority of respondents indicated that they definitely or probably would try parenteral nanoformulated antiretroviral therapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1807-13 |
| Number of pages | 7 |
| Journal | Nanomedicine |
| Volume | 8 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 2013 |
| Externally published | Yes |
Keywords
- Adolescent
- Adult
- Aged
- Anti-HIV Agents/therapeutic use
- Female
- HIV Infections/drug therapy
- Humans
- Male
- Middle Aged
- Patient Acceptance of Health Care/statistics & numerical data
- Young Adult
PubMed: MeSH publication types
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
